Big Pharma Is Pouring Into China — But They Are Not All Playing the Same Game

Three of the world's largest drugmakers have pledged a combined $18.5 billion to China in under three months. From the headlines, it looks like a coordinated land rush. It is not. AstraZeneca, Eli Lilly, and Novartis are each betting on China for fundamentally different reasons — and the divergence tells you more about where global pharma is headed than any single investment.

The sequence started on January 29, when AstraZeneca announced a $15 billion investment through 2030 during UK Prime Minister Keir Starmer's visit to Beijing. CEO Pascal Soriot framed it as the beginning of "an exciting next chapter" — but AstraZeneca's China chapter is already a long book. The company has operated there since 1993, runs four manufacturing sites across Wuxi, Taizhou, Qingdao, and Beijing that supply medicines to over 70 markets, and employs more than 20,000 people in-country.

What's new is the modality bet. AstraZeneca is building end-to-end cell therapy manufacturing in Shanghai, leveraging its 2024 acquisition of Gracell Biotechnologies to become the first global pharma with complete CAR-T capabilities in China. It's also constructing a radioconjugate production base in Guangzhou. The strategy is vertical: own the entire manufacturing chain for next-generation cancer therapies in China, then export to Asia-Pacific markets. AstraZeneca has also signed 16 licensing deals with 15 Chinese biotech partners since 2023 — the company is not just building factories, it is building a pipeline sourcing operation.

Eli Lilly's approach is narrower and more product-specific. On March 11, the company announced a $3 billion investment over the next decade, centered on building localized manufacturing and supply for oral solid dosage forms. Translation: this is about orforglipron, Lilly's once-daily oral GLP-1 agonist for obesity and type 2 diabetes. The company submitted a marketing application to China's NMPA at the end of 2025, and the investment is a bet that oral GLP-1s will be enormous in a market where injectable adoption faces cultural resistance and cold-chain logistics are harder outside tier-one cities.

Lilly's $3 billion is a capacity play for a single blockbuster-in-waiting. If orforglipron clears NMPA review, local manufacturing means faster supply, lower cost of goods, and a structural advantage over Novo Nordisk's injectable-heavy portfolio in China.

Novartis's commitment, announced today, is the smallest in dollar terms — 3.3 billion yuan, roughly $480 million — but arguably the most revealing about where value is actually moving. Patrick Horber, president of Novartis's international unit, told China Daily in a March 12 interview that 49 percent of the company's business development deal value now comes from China-originated assets, up from less than 10 percent a few years ago. Much of that value, he said, went into early-stage deals.

That statistic is the buried lede. Novartis is not primarily building factories or manufacturing capacity in China. It is hunting for molecules. The company has wrapped up construction on a radioligand therapy manufacturing site in Haiyan, Zhejiang province — a 600 million yuan ($87 million) facility for cancer treatments — but the strategic emphasis is on partnering with Chinese biotechs for licensing and co-development. Novartis wants to find innovations locally and bring them to the rest of the world.

Horber also dropped a number that deserves more attention: in 2025, China's NMPA approved 76 new drugs compared to 46 by the FDA. In 2024, the two agencies were nearly tied at 48 and 50. The regulatory gap did not just close — China overtook the United States in new drug approvals in a single year. China also now lists more clinical trials than the US does.

"That just shows how China's entire regulatory reform has changed to allow it to approve innovations much faster," Horber said. Novartis had 13 drug approvals in China last year, with two more already in 2026.

The pattern across all three companies is real but it is not what it looks like from the outside. This is not a coordinated hedge against US drug pricing pressure, and it is not reshoring in reverse. Each company is responding to a different signal:

AstraZeneca sees China as a manufacturing and next-gen therapy hub that can serve all of Asia. It is building infrastructure. Lilly sees a massive market for a specific product and is building the supply chain to serve it. Novartis sees a biotech innovation ecosystem that is generating nearly half its deal pipeline and wants deeper access to the source.

The timing is not coincidental — all three announcements land in the diplomatic window around a Trump-Xi summit later this month, and each follows the model AstraZeneca set during Starmer's Beijing visit. But diplomatic window-dressing does not explain $18.5 billion in commitments. These companies are responding to structural changes in Chinese biotech: faster regulation, higher-quality innovation, and a domestic market that is the second-largest in the world for each of them.

Not everyone agrees the bet is worth making. Bristol Myers Squibb sold its 60 percent stake in Sino-American Shanghai Squibb Pharmaceuticals last September, ending a 43-year-old joint venture — the first US pharmaceutical JV in China. The sale was a quiet exit from a market where BMS had been since 1982.

The divergence between the companies doubling down and the one walking away is worth watching. Geopolitical risk has not disappeared. The 2024 arrest of AstraZeneca's former China president hangs over even the most bullish commitments. But $18.5 billion in less than ninety days suggests the three largest investors have each independently concluded that the risk of not being in China is greater than the risk of being there — even if their reasons for showing up are entirely different.